RT Journal Article
SR Electronic
T1 Metagenomic Study Revealed the Potential Role of the Gut Microbiome in Gout
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.21.19014142
DO 10.1101/2019.12.21.19014142
A1 Yongliang Chu
A1 Yufen Huang
A1 Qingchun Huang
A1 Xuefeng Xie
A1 Peng Wang
A1 Junxia Li
A1 Lifeng Liang
A1 Xiaohong He
A1 Yiqi Jiang
A1 Maojie Wang
A1 Jianhua Yang
A1 Xiumin Chen
A1 Chu Zhou
A1 Yue Zhao
A1 Fen Ding
A1 Yi Zhang
A1 Xiaodong Wu
A1 Xueyuan Bai
A1 JiaQi Wu
A1 Xia Wei
A1 XiangHong Chen
A1 Xiaodong Fang
A1 Zhang Wang
A1 Qiang Gao
A1 Silong Sun
A1 Runyue Huang
YR 2019
UL http://medrxiv.org/content/early/2019/12/27/2019.12.21.19014142.abstract
AB Emerging evidence has indicated an association between the gut microbiome and arthritis diseases including gout. This metagenomic study aims to investigate the possible role of gut microbiota in the development of gout. The results exhibit gout patients have higher abundance of Prevotella, Fusobacterium spp. and Bacteroides spp., whereas healthy controls have higher abundance of Enterobacteriaceae spp., butyrate-producing species, including Roseburia spp., Butyrivibrio spp. and Coprococcus spp. and anti-inflammatory Faecalibacterium prausnitzii. Functional analysis shows gut microbiome of gout patients have higher potential for fructose, mannose metabolism and lipid A biosynthesis, but lower potential for urate degradation and SCFAs production. Enterobacteriaceae spp. may contribute to urate degradation and provide immunostimulatory effect in healthy controls. A disease classifier based on gut microbiota shows positive performance in the discovery and validation cohorts (93.03% and 89.13% accuracy, respectively). The effect of uric-acid-lowering and anti-inflammatory drugs on the gut microbiome is mild. Integrative analyses of four additional diseases (obesity, type 2 diabetes, ankylosing spondylitis and rheumatoid arthritis) indicates gout seems to be more similar to autoimmune diseases than metabolic diseases. This work demonstrates an altered gut microbiota might influence the development of gout and provides new insights into the diagnosis and treatment of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from 1010 project from Guangdong Provincial Hospital of Chinese Medicine (No. YN10101906), the grants from Guangdong Provincial Hospital of Chinese Medicine (No. YN2018ML08, No. YN2018ZD06), Guangzhou Municipal Science and Technology supporting project (No. 201710010076), Guangdong Science and Technology Department (No. 2016A020226041) as well as Guangzhou science and technology program key projects (NO.201604020005).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe metagenomic shotgun sequencing data for all samples have been deposited in the CNGB Nucleotide Sequence Archive (CNSA) under accession code CNP0000284. Other data that support the findings of this study are available within the paper and its Supplementary Information files or from the corresponding author upon reasonable request.